AEZS:CA Aeterna Zentaris Inc

CAD 2.67 -0.09 -3.26087
Icon

Aeterna Zentaris Inc (AEZS:CA) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | TSX
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

CAD 2.67

-0.09 (-3.26)%

CAD 0.01B

179.00

N/A

CAD 5.67 (+112.36%)

Icon

AEZS:CA

Aeterna Zentaris Inc (CAD)
COMMON STOCK | TSX
CAD 2.67
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

CAD 0.01B

CAD 5.67 (+112.36%)

CAD 2.67

Aeterna Zentaris Inc (AEZS:CA) Stock Forecast

N/A

Based on the Aeterna Zentaris Inc stock forecast from 0 analysts, the average analyst target price for Aeterna Zentaris Inc is not available over the next 12 months. Aeterna Zentaris Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aeterna Zentaris Inc is Slightly Bearish, which is based on 4 positive signals and 8 negative signals. At the last closing, Aeterna Zentaris Inc’s stock price was CAD 2.67. Aeterna Zentaris Inc’s stock price has changed by -5.32% over the past week, -6.32% over the past month and -36.28% over the last year.

No recent analyst target price found for Aeterna Zentaris Inc
No recent average analyst rating found for Aeterna Zentaris Inc

Company Overview Aeterna Zentaris Inc

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secreti...Read More

https://www.zentaris.com

315 Sigma Drive, Summerville, SC, United States, 29486

0

December

CAD

Canada

Adjusted Closing Price for Aeterna Zentaris Inc (AEZS:CA)

Loading...

Unadjusted Closing Price for Aeterna Zentaris Inc (AEZS:CA)

Loading...

Share Trading Volume for Aeterna Zentaris Inc Shares

Loading...

Compare Performance of Aeterna Zentaris Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AEZS:CA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Aeterna Zentaris Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
FRX:CA
Fennec Pharmaceuticals Inc 0.00 (0.00%) CAD0.39B 30.20 -33.83

ETFs Containing AEZS:CA

Symbol Name AEZS:CA's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Aeterna Zentaris Inc (AEZS:CA) Stock

Stock Target Advisor's fundamental analysis for Aeterna Zentaris Inc's stock is Slightly Bearish.

Unfortunately we do not have enough data on AEZS:CA's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on AEZS:CA's stock to indicate what its average analyst target is.

AEZS:CA stock's Price/Earning ratio is 13.60. Our analysis grades AEZS:CA stock's Price / Earning ratio at C-. This means that AEZS:CA stock's Price/Earning ratio is above 29% of the stocks in the Biotechnology sector in the TSX exchange. Based on this AEZS:CA may be undervalued for its sector.

The last closing price of AEZS:CA's stock was CAD 2.67.

The most recent market capitalization for AEZS:CA is CAD 0.01B.

Unfortunately we do not have enough analyst data on AEZS:CA's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Aeterna Zentaris Inc's stock.

As per our most recent records Aeterna Zentaris Inc has 0 Employees.

Aeterna Zentaris Inc's registered address is 315 Sigma Drive, Summerville, SC, United States, 29486. You can get more information about it from Aeterna Zentaris Inc's website at https://www.zentaris.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...